With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...

More research is needed to see how this factor could inform risk tools and whether addressing it reduces future disease.

Even modern cancer treatments appear risky for the heart, especially if the radiation dose to the LAD is high.

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

It’s “time to get rid of this age-old practice,” said Sripal Bangalore, who noted that patients are happier when not fasting.

The data raise questions about valve hemodynamics and the role of early imaging to stay ahead of clinical and subclinical ...

Overall, though, the meta-analysis identified a reduction in ischemia—but not in hard outcomes—with early treatment.

The DCB looks good in select cases, but given its high price tag, exactly when to use it is still up for discussion, say ...

A one-stop approach resulted in a new diagnosis of HF for 3% of the clinic’s visitors, who then were referred for timely ...

Procedural planning and attention to detail can help, but heart teams should be realistic about what lies ahead, experts say.

PRESTIGE-AF is the first of the larger trials in this scenario to report results. More data are needed to help guide ...

Seeing is believing. Patients shown proof of calcification adhered better to statins; those without CAC avoided overtreatment ...